JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea.
Curr Top Med Chem
PUBLISHED: 10-29-2014
Show Abstract
Hide Abstract
alkaloids are a group of naturally occurring chemical compounds that contain mostly basic nitrogen atoms. In particular berberine is a quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids with anti-lipogenic and hypoglycemic effects. On the other hand, mate plant has reported to have high antioxidant potential, including an inhibitory ability against plasma and LDL oxidation.
Related JoVE Video
The effects of canrenone on inflammatory markers in patients with metabolic syndrome.
Ann. Med.
PUBLISHED: 10-17-2014
Show Abstract
Hide Abstract
Aim. To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. Methods. A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO). Results. We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo. Conclusion. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.
Related JoVE Video
Aptamers as Promising Molecular Recognition Elements for Diagnostics and Therapeutics in the Central Nervous System.
Nucleic Acid Ther
PUBLISHED: 10-09-2014
Show Abstract
Hide Abstract
Oligonucleotide aptamers are short, synthetic, single-stranded DNA or RNA able to recognize and bind to a multitude of targets ranging from small molecules to cells. Aptamers have emerged as valuable tools for fundamental research, clinical diagnosis, and therapy. Due to their small size, strong target affinity, lack of immunogenicity, and ease of chemical modification, aptamers are an attractive alternative to other molecular recognition elements, such as antibodies. Although it is a challenging environment, the central nervous system and related molecular targets present an exciting potential area for aptamer research. Aptamers hold promise for targeted drug delivery, diagnostics, and therapeutics. Here we review recent advances in aptamer research for neurotransmitter and neurotoxin targets, demyelinating disease and spinal cord injury, cerebrovascular disorders, pathologies related to protein aggregation (Alzheimer's, Parkinson's, and prions), brain cancer (glioblastomas and gliomas), and regulation of receptor function. Challenges and limitations posed by the blood brain barrier are described. Future perspectives for the application of aptamers to the central nervous system are also discussed.
Related JoVE Video
The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology.
ACS Chem Neurosci
PUBLISHED: 10-01-2014
Show Abstract
Hide Abstract
Most neurodegenerative diseases are characterized by the presence of protein aggregates. Alzheimer's disease (AD) is the most common cause of dementia in people over age 60. One of the histopathological hallmarks of AD is the presence of tau protein aggregates. Historically, it has been thought that paired helical filaments (PHFs) were the toxic form of tau that assembled to form neurofibrillary tangles (NFTs), but recently there has been evidence that tau oligomers, which form before PHFs and NFTs, could be the structures mediating neurodegeneration even before the fibrillary tau is deposited. Here, we discuss the recent advances in tau oligomer research, their implications on AD and other tauopathies, the mechanisms of tau turnover by the principal protein clearance systems (the proteasome and autophagy), and the potential use of tau oligomers as drug targets for the development of new therapeutic approaches.
Related JoVE Video
Isolated recurrence of secondary CNS lymphoma: case report and literature review.
J Neurol Surg Rep
PUBLISHED: 09-10-2014
Show Abstract
Hide Abstract
Isolated secondary central nervous system lymphoma (SCNSL) relapse is a rare disease. Consequently, standardized treatment regimens have yet to be developed. We present an interesting case of isolated SCNSL presenting with altered mental status and panhypopituitarism in a patient at low risk of developing the disease. We also review the related literature and discuss newer, more aggressive treatments for primary CNS lymphoma and SCNSL.
Related JoVE Video
Are there mild and serious metabolic syndromes? The need for a graded diagnosis.
J Cardiovasc Med (Hagerstown)
PUBLISHED: 08-28-2014
Show Abstract
Hide Abstract
Metabolic syndrome is an increasingly incident complex metabolic disorder, affecting around 30% of adults in the USA as well as in Europe. In a meta-analysis that evaluated cardiovascular risk associated with the third National Cholesterol Education Program definition of metabolic syndrome in 951?083 patients, metabolic syndrome was associated with a two-fold increase in the risk of coronary heart disease, cerebrovascular disease, all cardiovascular lethal and nonlethal cardiovascular diseases, and a 1.5-fold increase in the risk of all-cause mortality.In this context, the article in this issue of the Journal of Cardiovascular Medicine further stresses the concept that a 'full' metabolic syndrome, including all or almost all its potential components, is associated with an earlier and more serious organ damage, at both cardiac and vascular levels, than the standard definition of metabolic syndrome on the basis of the presence of three out of five components. Moreover, it confirms the central role of waist circumference as the main metabolic syndrome component associated with early organ damage in the enrolled patients, in whom increased waist circumference could be considered as the clinical phenotype of insulin resistance. These data are relevant because they stress the need for a further definition of metabolic syndrome on the basis of its main clinical characteristics (i.e. insulin-resistance/central obesity) and a fix constellation of associated factors (i.e. mild hypertension, atherogenic dyslipidemia) in order to clearly identify those individuals needing a more aggressive diagnostic and therapeutic approach.
Related JoVE Video
Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.
J. Clin. Oncol.
PUBLISHED: 08-25-2014
Show Abstract
Hide Abstract
To perform the first meta-analysis of the efficacy of skin-directed therapies for cutaneous metastases.
Related JoVE Video
Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus.
J Clin Pharmacol
PUBLISHED: 08-20-2014
Show Abstract
Hide Abstract
The aim of this study was to evaluate if the new metformin powder formulation improves the treatment satisfaction in patients with type 2 diabetes, in a case-control clinical trial. We enrolled 602 subjects in therapy with metformin in tablets formulation and instructed them to take the same dose of metformin in the new powder formulation. At baseline, and after 6 months since the assumption of metformin powder, each patient answered the following questionnaires: the SF-36 Health Survey, the Diabetes Quality Of Life questionnaire Modified (DQOL/Mod) and the Diabetes Treatment Satisfaction Questionnaire (DTSQ). We also assessed at baseline, at 3 and 6 months: fasting plasma glucose (FPG) and post-prandial glucose (PPG), glycated hemoglobin (HbA1c ), fasting plasma insulin (FPI), and homeostasis model assessment index of insulin resistance (HOMA-IR). We observed a statistically significant reduction in HbA1c , FPG, PPG, FPI and HOMA-IR (p < 0.05 for all) with metformin powder. The DTSQ questionnaire showed a higher level of satisfaction linked to the assumption of metformin powder compared to the tablets formulation. In conclusion, metformin powder formulation seems to be more appropriate for the treatment of diabetic patients. The improvement of glycemic control suggests a better adherence to the powder formulation.
Related JoVE Video
Selection and characterization of a novel DNA aptamer for label-free fluorescence biosensing of ochratoxin A.
Toxins (Basel)
PUBLISHED: 08-15-2014
Show Abstract
Hide Abstract
Nucleic acid aptamers are emerging as useful molecular recognition tools for food safety monitoring. However, practical and technical challenges limit the number and diversity of available aptamer probes that can be incorporated into novel sensing schemes. This work describes the selection of novel DNA aptamers that bind to the important food contaminant ochratoxin A (OTA). Following 15 rounds of in vitro selection, sequences were analyzed for OTA binding. Two of the isolated aptamers demonstrated high affinity binding and selectivity to this mycotoxin compared to similar food adulterants. These sequences, as well as a truncated aptamer (minimal sequence required for binding), were incorporated into a SYBR® Green I fluorescence-based OTA biosensing scheme. This label-free detection platform is capable of rapid, selective, and sensitive OTA quantification with a limit of detection of 9 nM and linear quantification up to 100 nM.
Related JoVE Video
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Cancer
PUBLISHED: 08-08-2014
Show Abstract
Hide Abstract
Docetaxel plus prednisone is currently the standard first-line treatment in metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to assess the clinical activity and pharmacodynamic/pharmacogenetic profile of docetaxel plus prednisone in combination with metronomic cyclophosphamide in mCRPC patients.
Related JoVE Video
Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report.
Tumori
PUBLISHED: 07-31-2014
Show Abstract
Hide Abstract
In recent years, targeted agents have replaced cytokine therapy as the standard of care for patients with metastatic renal cell carcinoma.
Related JoVE Video
Diabetes: safety and efficacy of albiglutide-results from two trials.
Nat Rev Endocrinol
PUBLISHED: 07-29-2014
Show Abstract
Hide Abstract
Type 2 diabetes mellitus is associated with a poor quality of life and considerable health-care costs and can be difficult to control. The recent results from the HARMONY 3 and HARMONY 6 trials suggest that albiglutide is a safe and effective treatment option for patients with type 2 diabetes mellitus.
Related JoVE Video
A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters.
J. Biol. Regul. Homeost. Agents
PUBLISHED: 07-09-2014
Show Abstract
Hide Abstract
The aim of this study was to evaluate the effects of a combination of red yeast rice, Silybum marianum and octasonol compared to placebo on lipid profile, endothelial, and inflammatory parameters in low risk dislipidemic patients. One hundred and thirty-four dislipidemic patients were randomised to take placebo or a patented nutraceutical association in tablet form (Zeta ColestRT), 1 tablet /day (immediately after the dinner), for three months in a double-blind, placebo-controlled trial. At baseline and after 3 months the following were evaluated: body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), metalloprotineases-2 and -9 (MMP-2 and MMP-9), high sensitivity C-reactive protein (Hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). The nutraceutical combination decreased total cholesterol and low density lipoprotein cholesterol compared to baseline (p = 0.042, and p = 0.041, respectively) and to placebo (p = 0.039, and p = 0.037, respectively). Triglycerides were reduced by the active treatment (p = 0.039), but not by placebo, even if, in group to group comparison, no differences were recorded (p = 0.061). All adipocytokines were reduced by the nutraceutical combination, in particular p = 0.044 for sICAM-1, p = 0.045 for sVCAM-1, p = 0.040 for sE-selectin, p = 0.035 for MMP-2, p = 0.039 for MMP-9, p = 0.038 for Hs-CRP, p = 0.036 for TNF-α, and p = 0.036 for IL-6 compared to baseline, and p = 0.042 for sICAM-1, p = 0.043 for sVCAM-1, p = 0.042 for sE-selectin, p = 0.031 for MMP-2, p = 0.038 for MMP-9, p =0.038 for Hs-CRP, and p = 0.043 for TNF-alpha, espectively, compared to placebo. We can conclude that a combination of red yeast rice, Silybum marianum and octasonol was effective in improving lipid profile, endothelial, and inflammatory parameters in low risk dislipidemic patients.
Related JoVE Video
Sunitinib, pazopanib or sorafenib for the treatment of patients with late-relapsing (>5 years) metastatic renal cell carcinoma.
J. Urol.
PUBLISHED: 07-07-2014
Show Abstract
Hide Abstract
Late recurrence of renal cell carcinoma (RCC) is not a rare event. The aim of this retrospective study was to investigate the clinico-pathological features and the outcome of patients (pts) treated with sorafenib, sunitinib and pazopanib for late-relapsing renal cell carcinoma (LR-RCC).
Related JoVE Video
A polystyrene-based microfluidic device with three-dimensional interconnected microporous walls for perfusion cell culture.
Biomicrofluidics
PUBLISHED: 07-01-2014
Show Abstract
Hide Abstract
In this article, we present a simple, rapid prototyped polystyrene-based microfluidic device with three-dimensional (3D) interconnected microporous walls for long term perfusion cell culture. Patterned 3D interconnected microporous structures were created by a chemical treatment together with a protective mask and the native hydrophobic nature of the microporous structures were selectively made hydrophilic using oxygen plasma treatment together with a protective mask. Using this polystyrene-based cell culture microfluidic device, we successfully demonstrated the support of four days perfusion cell culture of hepatocytes (C3A cells).
Related JoVE Video
Upper Urinary Tract Abnormalities: A Case of Bilateral Kidneys Within a Left-sided Omphalocele.
Urology
PUBLISHED: 06-24-2014
Show Abstract
Hide Abstract
Children with omphalocele, exstrophy, imperforate anus, and spinal defects complex present with the most severe form of birth defects in the exstrophy-epispadias spectrum. Prenatal diagnosis is difficult, but improved survival over the past several decades makes understanding the potential anatomic manifestations imperative for expeditious and appropriate surgical care. The upper urinary tract is often normal in children with omphalocele, exstrophy, imperforate anus, and spinal defects complex, but malposition of one of the kidneys has previously been reported. We present the first case of bilateral kidney herniation into the omphalocele sac.
Related JoVE Video
Decreasing excessive functional communication responses while treating destructive behavior using response restriction.
Res Dev Disabil
PUBLISHED: 06-20-2014
Show Abstract
Hide Abstract
Functional communication training (FCT) is an established treatment for destructive behavior that missucceeds in about 37% of cases when the reinforcement schedule for the functional communication response (FCR) is thinned using multiples schedules (mult FCT; Hagopian, Boelter, & Jarmolowicz, 2011). In this investigation, we evaluated the use of response restriction FCT (RR FCT) in a cohort of patients with poorly differentiated responding of the FCR during mult FCT. Results showed that (a) RR FCT maintained high rates of correct FCRs during the reinforcement component of RR FCT without increasing destructive behavior; (b) children displayed highly discriminated FCRs when an FCR card and a control card were simultaneously available during the reinforcement component of RR FCT; and (c) near-zero rates of destructive behavior were observed during the last five sessions of the terminal reinforcement schedule. Results are discussed relative to differences between mult FCT and RR FCT and successive and simultaneous discriminations.
Related JoVE Video
Modulatory effect of three antibiotics on uterus bovine contractility in vitro and likely therapeutic approaches in reproduction.
Theriogenology
PUBLISHED: 05-15-2014
Show Abstract
Hide Abstract
This in vitro study investigates the modulatory effect of three antibiotics (amoxicillin, enrofloxacin, and rifaximin) on contractility of the bovine uterine tissue in follicular and luteal phases. The effects of these antibiotics at three single doses (10(-6), 10(-5), and 10(-4) M) on their basal contractility were evaluated in isolated organ bath. The functionality of the strip throughout the experiment was evaluated by a dose of carbachol (10(-5) M); the obtained effect had to be repeatable (difference of ?20%) that is comparable to that induced by the previous administration of the same substance. The results demonstrate the different modulatory activities of these antibiotics on uterine contractility in follicular and luteal phases. The effects induced by amoxicillin and enrofloxacin are opposite: the first relaxes and the second increases the uterine contractility in both cycle phases. Instead, the activity of rifaximin varies depending on the phase of estrous cycle: it increases in the follicular phase and relaxes in the luteal phase. The obtained data provide the hypothesis of possible implications of these drugs in the pharmacologic modulation of uterine contractions. Their action at this level, associated with their specific antimicrobial effects, could suggest using these antibiotics for the treatment of diseases related to postpartum or infections that may occur in pregnant cattle, by virtue of their effects on myometrial contractility too.
Related JoVE Video
Dietary and nutraceutical approach to type 2 diabetes.
Arch Med Sci
PUBLISHED: 05-13-2014
Show Abstract
Hide Abstract
Nutritional medical treatment is the first step to achieve adequate glycemic control and prevent diabetic complications. Lifestyle changes include moderate weight loss (7%) and regular physical activity (150 min/week). The appropriate diet composition is < 30% total fat, < 10% saturated fats, > 15 g/1000 kcal fiber, half soluble, 45-60% of carbohydrates with amoderate intake of sugar (50 g/day) and protein intake of 15-20% of the total calories a day. Patients need to limit the intake of saturated fats to < 7% of the daily calorie intake. Monounsaturated fatty acids such as olive oil and other vegetable oils are recommended. L-carnitine, ?-lipoic acid, berberine and ?-3 fatty acids can be useful supplements.
Related JoVE Video
Constraints on cosmic strings from the LIGO-Virgo gravitational-wave detectors.
J Aasi, J Abadie, B P Abbott, R Abbott, T Abbott, M R Abernathy, T Accadia, F Acernese, C Adams, T Adams, R X Adhikari, C Affeldt, M Agathos, N Aggarwal, O D Aguiar, P Ajith, B Allen, A Allocca, E Amador Ceron, D Amariutei, R A Anderson, S B Anderson, W G Anderson, K Arai, M C Araya, C Arceneaux, J Areeda, S Ast, S M Aston, P Astone, P Aufmuth, C Aulbert, L Austin, B E Aylott, S Babak, P T Baker, G Ballardin, S W Ballmer, J C Barayoga, D Barker, S H Barnum, F Barone, B Barr, L Barsotti, M Barsuglia, M A Barton, I Bartos, R Bassiri, A Basti, J Batch, J Bauchrowitz, Th S Bauer, M Bebronne, B Behnke, M Bejger, M G Beker, A S Bell, C Bell, I Belopolski, G Bergmann, J M Berliner, D Bersanetti, A Bertolini, D Bessis, J Betzwieser, P T Beyersdorf, T Bhadbhade, I A Bilenko, G Billingsley, J Birch, M Bitossi, M A Bizouard, E Black, J K Blackburn, L Blackburn, D Blair, M Blom, O Bock, T P Bodiya, M Boer, C Bogan, C Bond, F Bondu, L Bonelli, R Bonnand, R Bork, M Born, V Boschi, S Bose, L Bosi, J Bowers, C Bradaschia, P R Brady, V B Braginsky, M Branchesi, C A Brannen, J E Brau, J Breyer, T Briant, D O Bridges, A Brillet, M Brinkmann, V Brisson, M Britzger, A F Brooks, D A Brown, D D Brown, F Brückner, T Bulik, H J Bulten, A Buonanno, D Buskulic, C Buy, R L Byer, L Cadonati, G Cagnoli, J Calderón Bustillo, E Calloni, J B Camp, P Campsie, K C Cannon, B Canuel, J Cao, C D Capano, F Carbognani, L Carbone, S Caride, A Castiglia, S Caudill, M Cavaglià, F Cavalier, R Cavalieri, G Cella, C Cepeda, E Cesarini, R Chakraborty, T Chalermsongsak, S Chao, P Charlton, E Chassande-Mottin, X Chen, Y Chen, A Chincarini, A Chiummo, H S Cho, J Chow, N Christensen, Q Chu, S S Y Chua, S Chung, G Ciani, F Clara, D E Clark, J A Clark, F Cleva, E Coccia, P-F Cohadon, A Colla, M Colombini, M Constancio, A Conte, R Conte, D Cook, T R Corbitt, M Cordier, N Cornish, A Corsi, C A Costa, M W Coughlin, J-P Coulon, S Countryman, P Couvares, D M Coward, M Cowart, D C Coyne, K Craig, J D E Creighton, T D Creighton, S G Crowder, A Cumming, L Cunningham, E Cuoco, K Dahl, T Dal Canton, M Damjanic, S L Danilishin, S D'Antonio, K Danzmann, V Dattilo, B Daudert, H Daveloza, M Davier, G S Davies, E J Daw, R Day, T Dayanga, R De Rosa, G Debreczeni, J Degallaix, W Del Pozzo, E Deleeuw, S Deleglise, T Denker, T Dent, H Dereli, V Dergachev, R DeRosa, R DeSalvo, S Dhurandhar, L Di Fiore, A Di Lieto, I Di Palma, A Di Virgilio, M Diaz, A Dietz, K Dmitry, F Donovan, K L Dooley, S Doravari, M Drago, R W P Drever, J C Driggers, Z Du, J-C Dumas, S Dwyer, T Eberle, M Edwards, A Effler, P Ehrens, J Eichholz, S S Eikenberry, G Endrőczi, R Essick, T Etzel, K Evans, M Evans, T Evans, M Factourovich, V Fafone, S Fairhurst, Q Fang, S Farinon, B Farr, W Farr, M Favata, D Fazi, H Fehrmann, D Feldbaum, I Ferrante, F Ferrini, F Fidecaro, L S Finn, I Fiori, R Fisher, R Flaminio, E Foley, S Foley, E Forsi, N Fotopoulos, J-D Fournier, S Franco, S Frasca, F Frasconi, M Frede, M Frei, Z Frei, A Freise, R Frey, T T Fricke, P Fritschel, V V Frolov, M-K Fujimoto, P Fulda, M Fyffe, J Gair, L Gammaitoni, J Garcia, F Garufi, N Gehrels, G Gemme, E Genin, A Gennai, L Gergely, S Ghosh, J A Giaime, S Giampanis, K D Giardina, A Giazotto, S Gil-Casanova, C Gill, J Gleason, E Goetz, R Goetz, L Gondan, G González, N Gordon, M L Gorodetsky, S Gossan, S Gossler, R Gouaty, C Graef, P B Graff, M Granata, A Grant, S Gras, C Gray, R J S Greenhalgh, A M Gretarsson, C Griffo, P Groot, H Grote, K Grover, S Grunewald, G M Guidi, C Guido, K E Gushwa, E K Gustafson, R Gustafson, B Hall, E Hall, D Hammer, G Hammond, M Hanke, J Hanks, C Hanna, J Hanson, J Harms, G M Harry, I W Harry, E D Harstad, M T Hartman, K Haughian, K Hayama, J Heefner, A Heidmann, M Heintze, H Heitmann, P Hello, G Hemming, M Hendry, I S Heng, A W Heptonstall, M Heurs, S Hild, D Hoak, K A Hodge, K Holt, M Holtrop, T Hong, S Hooper, T Horrom, D J Hosken, J Hough, E J Howell, Y Hu, Z Hua, V Huang, E A Huerta, B Hughey, S Husa, S H Huttner, M Huynh, T Huynh-Dinh, J Iafrate, D R Ingram, R Inta, T Isogai, A Ivanov, B R Iyer, K Izumi, M Jacobson, E James, H Jang, Y J Jang, P Jaranowski, F Jiménez-Forteza, W W Johnson, D Jones, D I Jones, R Jones, R J G Jonker, L Ju, Haris K, P Kalmus, V Kalogera, S Kandhasamy, G Kang, J B Kanner, M Kasprzack, R Kasturi, E Katsavounidis, W Katzman, H Kaufer, K Kaufman, K Kawabe, S Kawamura, F Kawazoe, F Kéfélian, D Keitel, D B Kelley, W Kells, D G Keppel, A Khalaidovski, F Y Khalili, E A Khazanov, B K Kim, C Kim, K Kim, N Kim, W Kim, Y-M Kim, E J King, P J King, D L Kinzel, J S Kissel, S Klimenko, J Kline, S Koehlenbeck, K Kokeyama, V Kondrashov, S Koranda, W Z Korth, I Kowalska, D Kozak, A Kremin, V Kringel, A Królak, C Kucharczyk, S Kudla, G Kuehn, A Kumar, P Kumar, R Kumar, R Kurdyumov, P Kwee, M Landry, B Lantz, S Larson, P D Lasky, C Lawrie, A Lazzarini, A le Roux, P Leaci, E O Lebigot, C-H Lee, H K Lee, H M Lee, J Lee, M Leonardi, J R Leong, N Leroy, N Letendre, B Levine, J B Lewis, V Lhuillier, T G F Li, A C Lin, T B Littenberg, V Litvine, F Liu, H Liu, Y Liu, Z Liu, D Lloyd, N A Lockerbie, V Lockett, D Lodhia, K Loew, J Logue, A L Lombardi, M Lorenzini, V Loriette, M Lormand, G Losurdo, J Lough, J Luan, M J Lubinski, H Lück, A P Lundgren, J MacArthur, E Macdonald, B Machenschalk, M MacInnis, D M Macleod, F Magaña-Sandoval, M Mageswaran, K Mailand, E Majorana, I Maksimovic, V Malvezzi, N Man, G M Manca, I Mandel, V Mandic, V Mangano, M Mantovani, F Marchesoni, F Marion, S Márka, Z Márka, A Markosyan, E Maros, J Marque, F Martelli, I W Martin, R M Martin, L Martinelli, D Martynov, J N Marx, K Mason, A Masserot, T J Massinger, F Matichard, L Matone, R A Matzner, N Mavalvala, G May, N Mazumder, G Mazzolo, R McCarthy, D E McClelland, S C McGuire, G McIntyre, J McIver, D Meacher, G D Meadors, M Mehmet, J Meidam, T Meier, A Melatos, G Mendell, R A Mercer, S Meshkov, C Messenger, M S Meyer, H Miao, C Michel, E E Mikhailov, L Milano, J Miller, Y Minenkov, C M F Mingarelli, S Mitra, V P Mitrofanov, G Mitselmakher, R Mittleman, B Moe, M Mohan, S R P Mohapatra, F Mokler, D Moraru, G Moreno, N Morgado, T Mori, S R Morriss, K Mossavi, B Mours, C M Mow-Lowry, C L Mueller, G Mueller, S Mukherjee, A Mullavey, J Munch, D Murphy, P G Murray, A Mytidis, M F Nagy, D Nanda Kumar, I Nardecchia, T Nash, L Naticchioni, R Nayak, V Necula, G Nelemans, I Neri, M Neri, G Newton, T Nguyen, E Nishida, A Nishizawa, A Nitz, F Nocera, D Nolting, M E Normandin, L K Nuttall, E Ochsner, J O'Dell, E Oelker, G H Ogin, J J Oh, S H Oh, F Ohme, P Oppermann, B O'Reilly, W Ortega Larcher, R O'Shaughnessy, C Osthelder, C D Ott, D J Ottaway, R S Ottens, J Ou, H Overmier, B J Owen, C Padilla, A Pai, C Palomba, Y Pan, C Pankow, F Paoletti, R Paoletti, M A Papa, H Paris, A Pasqualetti, R Passaquieti, D Passuello, M Pedraza, P Peiris, S Penn, A Perreca, M Phelps, M Pichot, M Pickenpack, F Piergiovanni, V Pierro, L Pinard, B Pindor, I M Pinto, M Pitkin, J Poeld, R Poggiani, V Poole, C Poux, V Predoi, T Prestegard, L R Price, M Prijatelj, M Principe, S Privitera, R Prix, G A Prodi, L Prokhorov, O Puncken, M Punturo, P Puppo, V Quetschke, E Quintero, R Quitzow-James, F J Raab, D S Rabeling, I Rácz, H Radkins, P Raffai, S Raja, G Rajalakshmi, M Rakhmanov, C Ramet, P Rapagnani, V Raymond, V Re, C M Reed, T Reed, T Regimbau, S Reid, D H Reitze, F Ricci, R Riesen, K Riles, N A Robertson, F Robinet, A Rocchi, S Roddy, C Rodríguez, M Rodruck, C Roever, L Rolland, J G Rollins, R Romano, G Romanov, J H Romie, D Rosińska, S Rowan, A Rüdiger, P Ruggi, K Ryan, F Salemi, L Sammut, V Sandberg, J Sanders, V Sannibale, I Santiago-Prieto, E Saracco, B Sassolas, B S Sathyaprakash, P R Saulson, R Savage, R Schilling, R Schnabel, R M S Schofield, E Schreiber, D Schuette, B Schulz, B F Schutz, P Schwinberg, J Scott, S M Scott, F Seifert, D Sellers, A S Sengupta, D Sentenac, A Sergeev, D Shaddock, S Shah, M S Shahriar, M Shaltev, B Shapiro, P Shawhan, D H Shoemaker, T L Sidery, K Siellez, X Siemens, D Sigg, D Simakov, A Singer, L Singer, A M Sintes, G R Skelton, B J J Slagmolen, J Slutsky, J R Smith, M R Smith, R J E Smith, N D Smith-Lefebvre, K Soden, E J Son, B Sorazu, T Souradeep, L Sperandio, A Staley, E Steinert, J Steinlechner, S Steinlechner, S Steplewski, D Stevens, A Stochino, R Stone, K A Strain, N Straniero, S Strigin, A S Stroeer, R Sturani, A L Stuver, T Z Summerscales, S Susmithan, P J Sutton, B Swinkels, G Szeifert, M Tacca, D Talukder, L Tang, D B Tanner, S P Tarabrin, R Taylor, A P M ter Braack, M P Thirugnanasambandam, M Thomas, P Thomas, K A Thorne, K S Thorne, E Thrane, V Tiwari, K V Tokmakov, C Tomlinson, A Toncelli, M Tonelli, O Torre, C V Torres, C I Torrie, F Travasso, G Traylor, M Tse, D Ugolini, C S Unnikrishnan, H Vahlbruch, G Vajente, M Vallisneri, J F J van den Brand, C Van Den Broeck, S van der Putten, M V van der Sluys, J van Heijningen, A A van Veggel, S Vass, M Vasúth, R Vaulin, A Vecchio, G Vedovato, J Veitch, P J Veitch, K Venkateswara, D Verkindt, S Verma, F Vetrano, A Viceré, R Vincent-Finley, J-Y Vinet, S Vitale, B Vlcek, T Vo, H Vocca, C Vorvick, W D Vousden, D Vrinceanu, S P Vyachanin, A Wade, L Wade, M Wade, S J Waldman, M Walker, L Wallace, Y Wan, J Wang, M Wang, X Wang, A Wanner, R L Ward, M Was, B Weaver, L-W Wei, M Weinert, A J Weinstein, R Weiss, T Welborn, L Wen, P Wessels, M West, T Westphal, K Wette, J T Whelan, S E Whitcomb, D J White, B F Whiting, S Wibowo, K Wiesner, C Wilkinson, L Williams, R Williams, T Williams, J L Willis, B Willke, M Wimmer, L Winkelmann, W Winkler, C C Wipf, H Wittel, G Woan, J Worden, J Yablon, I Yakushin, H Yamamoto, C C Yancey, H Yang, D Yeaton-Massey, S Yoshida, H Yum, M Yvert, A Zadrożny, M Zanolin, J-P Zendri, F Zhang, L Zhang, C Zhao, H Zhu, X J Zhu, N Zotov, M E Zucker, J Zweizig, .
Phys. Rev. Lett.
PUBLISHED: 04-04-2014
Show Abstract
Hide Abstract
Cosmic strings can give rise to a large variety of interesting astrophysical phenomena. Among them, powerful bursts of gravitational waves (GWs) produced by cusps are a promising observational signature. In this Letter we present a search for GWs from cosmic string cusps in data collected by the LIGO and Virgo gravitational wave detectors between 2005 and 2010, with over 625 days of live time. We find no evidence of GW signals from cosmic strings. From this result, we derive new constraints on cosmic string parameters, which complement and improve existing limits from previous searches for a stochastic background of GWs from cosmic microwave background measurements and pulsar timing data. In particular, if the size of loops is given by the gravitational backreaction scale, we place upper limits on the string tension G? below 10(-8) in some regions of the cosmic string parameter space.
Related JoVE Video
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Metab. Clin. Exp.
PUBLISHED: 03-22-2014
Show Abstract
Hide Abstract
To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia.
Related JoVE Video
A case of scrotal venous malformation mimicking a failed varicocelectomy.
BMJ Case Rep
PUBLISHED: 03-22-2014
Show Abstract
Hide Abstract
A 21-year-old man presented to interventional radiology department with several years of left scrotal pain, which exacerbated by prolonged standing and walking. The patient had undergone a left varicocelectomy at the age of 10, after which he had a persistent scrotal mass. As he grew older, the left scrotal mass continued to increase in size, and symptoms progressively worsened. Physical examination revealed a non-tender, firm left scrotal mass which remained unchanged in size after Valsalva manoeuvres. Initial ultrasound examination revealed an extratesticular, intrascrotal mass with minimal internal flow. MRI revealed a heterogeneously enhancing, low-flow venous malformation centred in the midscrotum involving multiple tissue planes. Two sessions of percutaneous sclerotherapy failed to relieve his pain. Three months after the second sclerotherapy, the patient underwent surgical resection. At the time of his postoperative visit, his left scrotal pain had significantly improved and pain with prolonged standing and walking had resolved completely.
Related JoVE Video
Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study.
J Am Soc Hypertens
PUBLISHED: 03-19-2014
Show Abstract
Hide Abstract
The aim of this study was to evaluate enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to enalapril 20 mg, lercanidipine 10 mg, or enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-? (TNF-?). We recorded a decrease of BP in all groups, with the enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not enalapril, improved Lp(a) levels compared with baseline, with enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if enalapril/lercanidipine combination was more effective than single monotherapies. TNF-? and Hs-CRP were greater reduced by enalapril/lercanidipine combination compared with enalapril (P < .05 for both). The enalapril/lercanidipine fixed combination was more effective than single monotherapies in decreasing BP, but also in improving markers of cardiovascular risk stratification in hypertensive patients.
Related JoVE Video
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes.
Diabet. Med.
PUBLISHED: 03-01-2014
Show Abstract
Hide Abstract
To compare the effects of vildagliptin with those of glimepiride on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes mellitus receiving metformin treatment.
Related JoVE Video
Comparison of outcomes after TURP versus photoselective vaporization of the prostate with respect to trainee involvement utilizing ACS NSQIP.
Prostate Cancer Prostatic Dis.
PUBLISHED: 02-07-2014
Show Abstract
Hide Abstract
Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvement using an independent national surgical database.
Related JoVE Video
Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: a 12-years follow-up of the Brisighella Heart Study historical cohort.
Diabetes Res. Clin. Pract.
PUBLISHED: 02-04-2014
Show Abstract
Hide Abstract
To identify and quantify the role of different risk factors in the long-term development of IFG and T2DM in a rural Italian population sample with family history of T2DM.
Related JoVE Video
Why mothers accompany adolescent and young adult childhood cancer survivors to follow-up clinic visits.
J Pediatr Oncol Nurs
PUBLISHED: 01-22-2014
Show Abstract
Hide Abstract
Parents often accompany adolescent and young adult (AYA) pediatric cancer survivors to follow-up oncology clinic visits and remain involved in their care, although little is known about their reasons for doing so.
Related JoVE Video
Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments.
Atherosclerosis
PUBLISHED: 01-16-2014
Show Abstract
Hide Abstract
to evaluate the main factors associated with long-term persistence in fully paid lipid-lowering treatment.
Related JoVE Video
Pharmacologic approaches to the aging athlete.
Sports Health
PUBLISHED: 01-16-2014
Show Abstract
Hide Abstract
As America's baby boomer population matures, there is an increasing interest in supplements that can delay or oppose the aging process. This antiaging movement has exploded over the past decade. While most supplements are not supported by scientific literature or government controls, a number of products have been the subject of significant scientific inquiry. Hormone replacement therapy, including testosterone and growth hormone, has mixed results, and antioxidative strategies are supported by basic science but lack clinical evidence-based outcomes. While the process of aging has become better understood leading to more rational approaches to combat its effects on health, the clinician is reminded to carefully discern between the science and marketing that is available in this area.
Related JoVE Video
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
J Clin Pharm Ther
PUBLISHED: 01-14-2014
Show Abstract
Hide Abstract
There is considerable interest in pharmacogenetic and molecular biomarkers. Our aim was to evaluate the effects of enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients, such as lipoprotein(a) [Lp(a)], soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L) and serum myeloperoxidase (MPO).
Related JoVE Video
Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria.
Expert Opin Pharmacother
PUBLISHED: 01-13-2014
Show Abstract
Hide Abstract
To compare the effect of adding canrenone or hydrochlorothiazide (HCTZ) to valsartan/amlodipine combination on urinary albumin excretion (UAE) in microalbuminuric type 2 diabetic hypertensives.
Related JoVE Video
Smart materials based on DNA aptamers: taking aptasensing to the next level.
Sensors (Basel)
PUBLISHED: 01-10-2014
Show Abstract
Hide Abstract
"Smart" materials are an emerging category of multifunctional materials with physical or chemical properties that can be controllably altered in response to an external stimulus. By combining the standard properties of the advanced material with the unique ability to recognize and adapt in response to a change in their environment, these materials are finding applications in areas such as sensing and drug delivery. While the majority of these materials are responsive to physical or chemical changes, a particularly exciting area of research seeks to develop smart materials that are sensitive to specific molecular or biomolecular stimuli. These systems require the integration of a molecular recognition probe specific to the target molecule of interest. The ease of synthesis and labeling, low cost, and stability of DNA aptamers make them uniquely suited to effectively serve as molecular recognition probes in novel smart material systems. This review will highlight current work in the area of aptamer-based smart materials and prospects for their future applications.
Related JoVE Video
Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
PLoS ONE
PUBLISHED: 01-01-2014
Show Abstract
Hide Abstract
Phambili, the Merck (MRK)-Adenovirus Type 5 (Ad5) HIV-1 gag/pol/nef subtype B vaccine study, conducted in South Africa, suspended enrollment and vaccination when companion study, Step, was found non-efficacious. Although the vaccine did not prevent HIV-1 infection or lower viral-load setpoint, immune responses recognized clades B and C HIV-1 subtypes. We investigated predictors of the vaccine-induced antigen-specific immune responses.
Related JoVE Video
Metastatic retroperitoneal hemangiopericytoma.
Can J Urol
PUBLISHED: 12-17-2013
Show Abstract
Hide Abstract
Hemangiopericytomas are rare mesenchymal lesions arising from pericytes within the walls of capillaries. They often have an unpredictable course. We present a case of a large retroperitoneal hemangiopericytoma in a 65-year-old woman who initially presented with upper gastrointestinal discomfort. Following exptirpative surgery, pathology was consistent with hemangiopericytoma of low malignant potential. Widespread metastasis was discovered on follow up imaging, 17 months following surgery. To our knowledge, this is the first case report demonstrating a primary retroperitoneal hemangioperictoma with confirmed metastases.
Related JoVE Video
Subcutaneous pellet testosterone replacement therapy: the "first steps" in treating men with spinal cord injuries.
J Am Osteopath Assoc
PUBLISHED: 11-29-2013
Show Abstract
Hide Abstract
The authors describe the case of a 36-year-old man who presented with hormone level concerns 6 months after a rock climbing accident that resulted in paraplegia. Hypogonadism was diagnosed, and the patient received subcutaneous pellet testosterone replacement therapy. Within 6 months, the patient had substantial improvement in muscle function and was able to take several steps with the assistance of crutches or a walker. This case highlights the potential improvement in quality of life and overall prognosis resulting from the subcutaneous pellet form of testosterone when used as part of the overall treatment plan in such patients. Considering the overwhelming preponderance of hypogonadism in men with spinal cord injuries, the standard of care for such patients should include screening, laboratory hormone evaluation, and prompt treatment for testosterone deficiency.
Related JoVE Video
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria.
Expert Opin Pharmacother
PUBLISHED: 11-07-2013
Show Abstract
Hide Abstract
Aim of this study was to compare the antiproteinuric effect of imidapril (I) and ramipril (R) in diabetic hypertensive patients with microalbuminuria.
Related JoVE Video
Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients.
J. Biol. Regul. Homeost. Agents
PUBLISHED: 10-25-2013
Show Abstract
Hide Abstract
Nutraceuticals and functional foods have attracted considerable interest as potential alternative therapies for treatment of different cardiovascular disorders and insulin resistance. We evaluated the efficacy of a combination of Berberis Aristata/Silybum Marianum extract (Berberol®) in a sample of overweight, dyslipidemic patients at low cardiovascular risk. We enrolled 105 Caucasian, euglycemic, overweight, dyslipidemic patients, of either sex. At baseline all patients underwent a 6 months run-in period during which they followed an adequate diet and practiced physical activity. At the end of the run-in period, patients were randomised to take placebo or a combination of Berberis aristata/Silybum marianum, 1 tablet during the lunch and 1 tablet during the dinner, for three months, in a double-blind, placebo-controlled design. Berberis aristata/Silybum marianum and placebo were then interrupted for 2 months (wash-out period), and all patients continued with only diet and physical activity. At the end of the wash-out period, patients re-started Berberis aristata/Silybum marianum or placebo twice a day for further 3 months. We evaluated during the run-in period, at randomisation, before and after the wash-out period these parameters: body weight and BMI, fasting plasma glucose, lipid profile, insulin resistance, retinol binding protein-4 (RBP-4), adiponectin (ADN), resistin. Total cholesterol, LDL-C, and Tg decreased, and HDL-C increase after 3 months of Berberis aristata/Silybum marianum, both compared to baseline and placebo. Berberis aristata/Silybum marianum decreased fasting plasma insulin, and HOMA-IR, both compared to baseline and to placebo. Moreover, there was a decrease of RBP-4, and resistin, and an increase of ADN after 3 months of Berberis aristata/Silybum marianum. All these positive effects disappeared after the wash-out period, and re-appeared after the re-introduction of the drug. We observed a significant correlation between HOMA-index decrease and resistin, and RBP-4 decrease, and between HOMA-index decrease and ADN increase in Berberis aristata/Silybum marianum group, but not in placebo group. Berberis aristata/Silybum marianum fixed combination seems to be safe and effective in improving lipid profile, but also in improving insulin resistance and adipocytokines levels.
Related JoVE Video
Conceptualizing prognostic awareness in advanced cancer: A systematic review.
J Health Psychol
PUBLISHED: 10-24-2013
Show Abstract
Hide Abstract
This systematic review synthesizes the complex literature on prognostic awareness in cancer. A total of 37 studies examining cancer patients understanding of their prognosis were included. Prognostic awareness definitions and assessment methods were inconsistent across studies. A surprisingly high percentage of patients (up to 75%) were unaware of their poor prognosis, and in several studies, even their cancer diagnosis (up to 96%), particularly in studies conducted outside of North America. This review highlights surprisingly low rates of prognostic awareness in patients with advanced cancer as well as discrepancies in prognostic awareness assessment, suggesting the need for empirically validated measures of prognostic awareness.
Related JoVE Video
Effects of canrenone in patients with metabolic syndrome.
Expert Opin Pharmacother
PUBLISHED: 08-28-2013
Show Abstract
Hide Abstract
Metabolic syndrome is becoming a common disease due to a rise in obesity rates among adults.
Related JoVE Video
Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients.
Expert Opin Biol Ther
PUBLISHED: 08-24-2013
Show Abstract
Hide Abstract
Relatively large number of dietary supplements and nutraceuticals have been studied for their supposed or demonstrated ability to reduce cholesterolemia in humans.
Related JoVE Video
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients.
Expert Opin Pharmacother
PUBLISHED: 07-25-2013
Show Abstract
Hide Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used for reducing pain and other symptoms in osteoarthritis (OA). NSAIDs have been associated with an increase in blood pressure (BP) in both normotensive and hypertensive individuals and a blunting effect on various anti-hypertensive medications. Acetaminophen effects on anti-hypertensive treatment, instead, are still a matter of debate.
Related JoVE Video
Related JoVE Video
Immobilization of DNA aptamers on polyester cloth for antigen detection by dot blot immunoenzymatic assay (aptablot).
J Nucleic Acids
PUBLISHED: 06-25-2013
Show Abstract
Hide Abstract
A simple dot blot immunoenzymatic assay system was developed using polyester cloth coated with an oligo-DNA aptamer to provide a high-affinity macroporous surface for the efficient capture of a model protein analyte (thrombin) in complex sample matrices such as foods. Bound thrombin was detected immunoenzymatically using a peroxidase-linked antithrombin antibody and a chromogenic substrate. A unique feature of this approach, which we have termed "aptablot," is the facile immobilization of DNA aptamers on the polyester surface by cross-linking with a brief exposure to ultraviolet light, and the simple assay format obviating the need for specialized instruments. The assay principle described herein should be broadly applicable to many situations where analytes must be detected in complex samples, with the main limiting factor being the availability of suitable DNA aptamers.
Related JoVE Video
Utility of AAOS OITE scores in predicting ABOS Part I outcomes: AAOS exhibit selection.
J Bone Joint Surg Am
PUBLISHED: 06-21-2013
Show Abstract
Hide Abstract
Residency programs commonly use performance on the Orthopaedic In-Training Examination (OITE) developed by the American Academy of Orthopaedic Surgeons (AAOS) to identify residents who are lagging behind their peers and at risk for failing Part I of the American Board of Orthopaedic Surgery (ABOS) Certifying Examination. This study was designed to investigate the utility of the OITE score as a predictor of ABOS Part I performance.
Related JoVE Video
Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure.
Expert Rev Cardiovasc Ther
PUBLISHED: 06-12-2013
Show Abstract
Hide Abstract
Diabetes is associated with left ventricular hypertrophy (LVH). This article reviews the assessment and management of LVH in Type 2 diabetic patients and the available evidence on blood-pressure management in these patients in order to reduce LVH. The best treatment of LVH starts with early identification and rapid implementation of adequate treatment, especially in populations at higher risk. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors should be the first-line therapy, because they are proven to be the most effective in reducing LVH in Type 2 diabetic patients. In patients where angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors are contraindicated or not tolerated, calcium-channel blockers should be the second option.
Related JoVE Video
Target-molecule-triggered rupture of aptamer-encapsulated polyelectrolyte microcapsules.
ACS Appl Mater Interfaces
PUBLISHED: 06-11-2013
Show Abstract
Hide Abstract
Polyelectrolyte microcapsules have great potential for serving as carriers for the delivery of their contents when triggered by an external stimulus. Aptamers are synthetic ssDNA or RNA that can bind to specific targets with high affinity and selectivity. Aptamers may retain these superior molecular recognition properties after encapsulation within polymer microcapsules. In this work, stable polyelectrolyte microcapsules with encapsulated aptamers were obtained by the layer-by-layer (LbL) method. Polyelectrolyte films were deposited onto a CaCO3 template that had been predoped with polystyrene sulfonate (PSS) and aptamer sequences (SA) that have an affinity for the dye sulforhodamine B (SRB). The PSS and aptamers are thought to serve as an internal scaffold supporting the microcapsule walls. These microcapsules would present target-molecule-triggered rupture properties. Microcapsule collapse was triggered by the binding of SRB to the encapsulated aptamer. The specificity of microcapsule collapse was investigated using a similar dye, tetramethylrosamine (TMR), which does not have affinity for SA. A high concentration of TMR did not lead to the collapse of the microcapsules. The effect of target binding on the microcapsules was confirmed by scanning electron microscopy (SEM) and confocal laser scanning microscopy (CLSM). These microcapsules may have potential applications in targeted delivery systems for the controlled release of drugs, pesticides, or other payloads.
Related JoVE Video
Related JoVE Video
Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model.
Blood
PUBLISHED: 05-29-2013
Show Abstract
Hide Abstract
Despite continued progress in the development of novel antiretroviral therapies, it has become increasingly evident that drug-based treatments will not lead to a functional or sterilizing cure for HIV(+) patients. In 2009, an HIV(+) patient was effectively cured of HIV following allogeneic transplantation of hematopoietic stem cells (HSCs) from a CCR5(-/-) donor. The utility of this approach, however, is severely limited because of the difficulty in finding matched donors. Hence, we studied the potential of HIV-resistant stem cells in the autologous setting in a nonhuman primate AIDS model and incorporated a fusion inhibitor (mC46) as the means for developing infection-resistant cells. Pigtail macaques underwent identical transplants and Simian-Human Immunodeficiency Virus (SHIV) challenge procedures with the only variation between control and mC46 macaques being the inclusion of a fusion-inhibitor expression cassette. Following SHIV challenge, mC46 macaques, but not control macaques, showed a positive selection of gene-modified CD4(+) T cells in peripheral blood, gastrointestinal tract, and lymph nodes, accounting for >90% of the total CD4(+) T-cell population. mC46 macaques also maintained high frequencies of SHIV-specific, gene-modified CD4(+) T cells, an increase in nonmodified CD4(+) T cells, enhanced cytotoxic T lymphocyte function, and antibody responses. These data suggest that HSC protection may be a potential alternative to conventional antiretroviral therapy in patients with HIV/AIDS.
Related JoVE Video
Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects.
Nutr Res
PUBLISHED: 05-12-2013
Show Abstract
Hide Abstract
Despite a recent health claim by the European Agency on Food Safety, the effect of high doses of dietary monacolin supplements from red yeast rice on cholesterolemia has not been tested in Italian subjects. Our aim via a crossover, double-blind, placebo-controlled randomized clinical trial was to test if a short-term treatment with 10 mg monacolins could improve lipid pattern, high-sensitivity C-reactive protein (hs-CRP), and vascular remodeling biomarkers in a small cohort of Mediterranean subjects. Thus, 25 healthy, mildly hypercholesterolemic subjects were enrolled, and after 4 weeks of a stabilization diet, subjects were randomized to the sequence placebo-washout-monacolins or monacolins-washout-placebo, with each period being 4 weeks long. At each study step, a complete lipid pattern, safety parameters, hs-CRP, and matrix metalloproteinases 2 and 9 levels were measured. When compared to the placebo group, monacolins-treated patients experienced a more favorable percent change in total cholesterol (-12.45%, 95% CI -16.19 to -8.71), low-density lipoprotein cholesterol (-21.99%, 95% CI -26.63 to -17.36), non-high-density lipoprotein cholesterol (-14.67%, 95% CI -19.22 to -10.11), matrix metalloproteinase 2 (-28.05%, 95% CI -35.18 to -20.93), matrix metalloproteinase 9 (-27.19%, 95% CI -36.21 to -18.15), and hs-CRP (-23.77%, 95% CI -30.54 to -17.01). No significant differences were observed in regards to triglycerides, high-density lipoprotein cholesterol, and safety parameters. On the basis of our data, we demonstrate that a 10-mg monacolin nutraceutical appears to safely reduce cholesterolemia, hs-CRP, and markers of vascular remodeling in Italian subjects. These results have to be confirmed in larger patient samples and longer studies.
Related JoVE Video
Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Can. J. Physiol. Pharmacol.
PUBLISHED: 04-23-2013
Show Abstract
Hide Abstract
The aim of this study was to evaluate the effects of exenatide on levels of serum adipocytokines and on ?-cell function. The study was conducted between 2008 and 2012. After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 ?g twice daily, or a group receiving the placebo, for 12 months. We evaluated body mass index (BMI), blood pressure, glycemic control, lipid profile, fasting plasma insulin (FPI), HOMA-IR, HOMA-?, fasting plasma proinsulin (FPPr), proinsulin : fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, retinol binding protein-4 (RBP-4), visfatin, omentin-1, and microalbuminuria. We used ELISA methods to assess the various parameters. Patients also underwent a combined euglycemic-hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation. After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level. Treatment with exenatide + metformin was superior to the placebo + metformin in increasing HOMA-?, C-peptide, and ?-cell function. Significant negative correlations were found between M value, an index of insulin sensitivity, and measured adipocytokines. In conclusion, the combination of exenatide + metformin plays a role in improving some adipocytokine levels, and is better than metformin alone. The significant negative correlation between M value and measured adipocytokines is another confirmation of the positive effects linked to the improvement in insulin sensitivity.
Related JoVE Video
Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate.
Arch Med Sci
PUBLISHED: 04-09-2013
Show Abstract
Hide Abstract
Familial combined hyperlipoproteinemia (FCHL) is a very common and aggressive genetic mixed hyperlipoproteinemia, with many features similar to that of the metabolic syndrome (MS). We aimed to evaluate whether the presence of the MS per se could account for a significant part of the elevated cardiovascular disease (CVD) risk associated with FCHL.
Related JoVE Video
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Eur J Gastroenterol Hepatol
PUBLISHED: 03-26-2013
Show Abstract
Hide Abstract
To compare pioglitazone or glibenclamide alone and in combination with rosuvastatin on hepatic steatosis in type 2 diabetic patients.
Related JoVE Video
Adipocytokine levels in obese and non-obese subjects: an observational study.
Inflammation
PUBLISHED: 03-08-2013
Show Abstract
Hide Abstract
We evaluated the levels of some inflammatory adipocytokines in 363 obese and 365 non-obese subjects. We measured: body mass index (BMI), waist circumference (WC), fasting plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment (HOMA) index, blood pressure, lipid profile, retinol binding protein-4 (RBP-4), vaspin, omentin-1, leptin, interleukin-6 (IL-6), visfatin, resistin, adiponectin (ADN), adipsin, tumor necrosis factor-? (TNF-?), and high sensitivity C-reactive protein (Hs-CRP). We observed higher BMI, WC, FPI, HOMA index, TC, LDL-C, RBP-4, leptin, IL-6, adipsin, Hs-CRP, vaspin, resistin and TNF-? levels, and lower visfatin, and ADN levels in obese compared to non-obese subjects. Higher WC correlated with lower ADN and visfatin levels, and higher vaspin levels. Higher HOMA index correlated with higher resistin, adipsin, RBP-4, and leptin concentrations, while higher leptin levels correlated with higher TNF-?, Hs-CRP, and IL-6 concentration, and lower ADN values. We confirmed obese subjects predisposition to develop dysmetabolic disease and hormonal dysfunctions.
Related JoVE Video
Evaluation of the positive effects on insulin-resistance and ?-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Pharmacol. Res.
PUBLISHED: 03-02-2013
Show Abstract
Hide Abstract
We evaluated the positive effects of vildagliptin in addition to metformin on glycemic control and ?-cell function in type 2 diabetic patients. One hundred and seventy-one type 2 diabetic patients were instructed to add vildaglipin 50mg twice a day or placebo to metformin for 12 months. Body mass index (BMI), glycemic control, fasting plasma insulin (FPI), HOMA-IR, HOMA-?, fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, vaspin, visfatin, and omentin-1 were evaluated. Before, and after 12 months since the addition of vildagliptin, patients underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation. Vildagliptin+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and insulin resistance measurements. Vildagliptin+metformin gave also a better increase of HOMA-?, and of all ?-cell parameters after the clamp. We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and omentin-1 obtained with vildagliptin+metformin. Vildagliptin, in addition to metformin, proved to be effective in improving ?-cell function and in reducing insulin resistance measurements.
Related JoVE Video
Effects of berberine on lipid profile in subjects with low cardiovascular risk.
Expert Opin Biol Ther
PUBLISHED: 02-27-2013
Show Abstract
Hide Abstract
To evaluate the efficacy as antihypercholesterolemic agent of berberine in patients with low cardiovascular risk.
Related JoVE Video
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
Eur J Pharm Sci
PUBLISHED: 02-23-2013
Show Abstract
Hide Abstract
Hypertension affects nearly 1 in 3 adults in the United States, and it is an important modifiable risk factor for coronary artery disease, heart failure, renal failure, and stroke. The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies.
Related JoVE Video
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Diabetes Technol. Ther.
PUBLISHED: 02-21-2013
Show Abstract
Hide Abstract
This study evaluated if triple oral therapy can be useful in improving glycemic control compared with metformin monotherapy and with a metformin and pioglitazone combination. Furthermore, we also compared a triple metformin+pioglitazone+glibenclamide combination with a metformin+pioglitazone+sitagliptin one.
Related JoVE Video
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.
Expert Opin Pharmacother
PUBLISHED: 02-17-2013
Show Abstract
Hide Abstract
The aim was to compare the antiproteinuric effect of aliskiren and ramipril in hypertensive patients with type 2 diabetes and microalbuminuria.
Related JoVE Video
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and ?-cell function: the triple oral therapy.
Diabet. Med.
PUBLISHED: 02-14-2013
Show Abstract
Hide Abstract
To evaluate which triple oral therapy between metformin + pioglitazone + sitagliptin and metformin + pioglitazone + glibenclamide can be more useful in improving glycaemic control and should be preferred in clinical practice.
Related JoVE Video
High resolution grating-assisted surface plasmon resonance fiber optic aptasensor.
Methods
PUBLISHED: 01-24-2013
Show Abstract
Hide Abstract
A surface plasmon resonance biochemical sensor based on a tilted fiber Bragg grating imprinted in a single mode fiber core is demonstrated. A 30-50 nm thick gold coating on the cladding of the fiber provides the support for surface plasmon waves whose interaction with attached biomolecules is monitored at near infrared wavelengths near 1,550 nm. The transmission spectrum of the sensor provides a fine comb of narrowband resonances that overlap with the broader absorption of the surface plasmon and thus provide a unique tool to measure small shifts of the plasmon with high accuracy. The attachment on the gold surfaces of aptamers with specific affinities for proteins provides the required target-analyte system and is shown to be functional in the framework of our sensing device. The implementation of the sensor either as a stand-alone device or as part of a multi-sensor platform is also described.
Related JoVE Video
Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies.
J Am Soc Hypertens
PUBLISHED: 01-17-2013
Show Abstract
Hide Abstract
The purpose of this study was to evaluate a fixed olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and some inflammatory markers compared with single-drug monotherapy. A total of 276 hypertensive patients were randomly assigned to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following at baseline and after 6 and 12 months: body weight, body mass index, systolic (SBP) and diastolic blood pressures (DBP), fasting plasma glucose (FPG), fasting plasma insulin (FPI), lipid profile, tumor necrosis factor-? (TNF-?), retinol binding protein-4 (RBP-4), and interleukins 6 and 7 (IL-6 and IL-7). At baseline, and after 6 and 12 months, patients underwent an euglycemic, hyperinsulinemic clamp. The olmesartan/amlodipine combination provided a greater decrease of SBP and DPB compared with amlodipine and olmesartan monotherapies. The olmesartan/amlodipine combination decreased FPG after 12 months compared with amlodipine monotherapy. The combination decreased FPI and homeostasis model assessment index and increased M value both compared with baseline and with olmesartan and amlodipine monotherapies. Olmesartan/amlodipine decreased IL-7, but not IL-6, compared with single drug components. The olmesartan/amlodipine combination is effective and safe in reducing blood pressure and has some additive effects not shown by single drugs, such as an improvement of IL-7.
Related JoVE Video
Ultrasensitive norovirus detection using DNA aptasensor technology.
PLoS ONE
PUBLISHED: 01-01-2013
Show Abstract
Hide Abstract
DNA aptamers were developed against murine norovirus (MNV) using SELEX (Systematic Evolution of Ligands by EXponential enrichment). Nine rounds of SELEX led to the discovery of AG3, a promising aptamer with very high affinity for MNV as well as for lab-synthesized capsids of a common human norovirus (HuNoV) outbreak strain (GII.3). Using fluorescence anisotropy, AG3 was found to bind with MNV with affinity in the low picomolar range. The aptamer could cross-react with HuNoV though it was selected against MNV. As compared to a non-specific DNA control sequence, the norovirus-binding affinity of AG3 was about a million-fold higher. In further tests, the aptamer also showed nearly a million-fold higher affinity for the noroviruses than for the feline calicivirus (FCV), a virus similar in size and structure to noroviruses. AG3 was incorporated into a simple electrochemical sensor using a gold nanoparticle-modified screen-printed carbon electrode (GNPs-SPCE). The aptasensor could detect MNV with a limit of detection of approximately 180 virus particles, for possible on-site applications. The lead aptamer candidate and the aptasensor platform show promise for the rapid detection and identification of noroviruses in environmental and clinical samples.
Related JoVE Video
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus.
Diabetes Obes Metab
PUBLISHED: 12-27-2011
Show Abstract
Hide Abstract
To evaluate the effect of aliskiren compared to amlodipine on QT duration and dispersion in hypertensive patients with type 2 diabetes.
Related JoVE Video
Profiles of Health Competence Beliefs Among Young Adult Survivors of Childhood Cancer.
J Adolesc Young Adult Oncol
PUBLISHED: 12-01-2011
Show Abstract
Hide Abstract
Purpose: The goal of this study was to identify profiles of young adult (YA)-aged cancer survivors beliefs about their health and well-being. Survivors beliefs and their associated psychosocial and demographic characteristics may be clinically useful in survivorship care. Patients and methods: YA survivors of pediatric leukemias (n=51), lymphomas (n=24), and solid tumors (n=44), aged 18-29 years old (N=119), were categorized using cluster analysis based on their responses to the Health Competence Beliefs Inventory, a measure assessing beliefs about their health, satisfaction with healthcare, autonomy, and cognitive competence. Profiles of beliefs generated by cluster analysis were examined using self-report measures of health problems, distress, demographics, and provider-reported health problems and cancer treatment intensity. Results: Three distinct clusters were identified: Adaptive (n=54), Low Autonomy (n=25), and Vulnerable (n=40). Adaptive survivors had positive beliefs, low distress, and minimal health problems. The Low Autonomy survivors were similar to those in the Adaptive cluster except they had low autonomy beliefs and the majority reported living with their parents. The Vulnerable cluster had more negative beliefs, the most medical problems, and the highest levels of distress. Conclusion: Health competence belief profiles identified unique subsets of YA survivors of pediatric cancer that have potentially distinct risk factors. Categorizing survivors by health belief patterns may help healthcare providers treat and educate their patients in ways that are tailored to individual survivors needs and risks.
Related JoVE Video
Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression.
Prostate Cancer Prostatic Dis.
PUBLISHED: 11-29-2011
Show Abstract
Hide Abstract
The majority of prostate cancers (CaP) are detected in early stages with uncertain prognosis. Therefore, an intensive effort is underway to define early predictive markers of CaP with aggressive progression characteristics.
Related JoVE Video
Development of a computerized adaptive test to assess health-related quality of life in adults with asthma.
J Asthma
PUBLISHED: 11-24-2011
Show Abstract
Hide Abstract
The purpose of this research was to calibrate an item bank for a computerized adaptive test (CAT) of asthma impact on health-related quality of life (HRQOL), test CAT versions of varying lengths, conduct preliminary validity testing, and evaluate item bank readability.
Related JoVE Video
Nifedipine and telmisartan for the treatment of hypertension: the TALENT study.
Expert Rev Cardiovasc Ther
PUBLISHED: 11-23-2011
Show Abstract
Hide Abstract
A combination of two drugs as initial treatment in patients with a high or very high cardiovascular risk profile is recommended. Nifedipine extended release (GITS) is a calcium-channel antagonist known to be metabolically neutral, to mildly slow the development of atherosclerosis in hypertensive subjects and to significantly decrease cardiovascular risk in diabetic patients. Telmisartan is highly selective for the angiotensin receptor 1, it gives a greater improvement in glycemic and lipid control compared with irbesartan, and it proved its superiority in improving insulin sensitivity compared with eprosartan. The TALENT study was aimed to determine whether combining low-dose nifedipine GITS at and telmisartan reduced ambulatory and clinic blood pressure more than the two components in monotherapy in hypertensive patients at high cardiovascular risk. The study shows that combination treatment with nifedipine GITS and telmisartan provides a greater and earlier blood pressure reduction than the combination components in monotherapy.
Related JoVE Video
Directional limits on persistent gravitational waves using LIGO S5 science data.
J Abadie, B P Abbott, R Abbott, M Abernathy, T Accadia, F Acernese, C Adams, R Adhikari, P Ajith, B Allen, G S Allen, E Amador Ceron, R S Amin, S B Anderson, W G Anderson, F Antonucci, M A Arain, M C Araya, M Aronsson, K G Arun, Y Aso, S M Aston, P Astone, D Atkinson, P Aufmuth, C Aulbert, S Babak, P Baker, G Ballardin, S Ballmer, D Barker, S Barnum, F Barone, B Barr, P Barriga, L Barsotti, M Barsuglia, M A Barton, I Bartos, R Bassiri, M Bastarrika, J Bauchrowitz, Th S Bauer, B Behnke, M G Beker, A Belletoile, M Benacquista, A Bertolini, J Betzwieser, N Beveridge, P T Beyersdorf, S Bigotta, I A Bilenko, G Billingsley, J Birch, S Birindelli, R Biswas, M Bitossi, M A Bizouard, E Black, J K Blackburn, L Blackburn, D Blair, B Bland, M Blom, C Boccara, O Bock, T P Bodiya, R Bondarescu, F Bondu, L Bonelli, R Bonnand, R Bork, M Born, S Bose, L Bosi, B Bouhou, M Boyle, S Braccini, C Bradaschia, P R Brady, V B Braginsky, J E Brau, J Breyer, D O Bridges, A Brillet, M Brinkmann, V Brisson, M Britzger, A F Brooks, D A Brown, R Budzyński, T Bulik, H J Bulten, A Buonanno, J Burguet-Castell, O Burmeister, D Buskulic, C Buy, R L Byer, L Cadonati, G Cagnoli, J Cain, E Calloni, J B Camp, E Campagna, P Campsie, J Cannizzo, K Cannon, B Canuel, J Cao, C Capano, F Carbognani, S Caride, S Caudill, M Cavaglià, F Cavalier, R Cavalieri, G Cella, C Cepeda, E Cesarini, T Chalermsongsak, E Chalkley, P Charlton, E Chassande-Mottin, S Chelkowski, Y Chen, A Chincarini, N Christensen, S S Y Chua, C T Y Chung, D Clark, J Clark, J H Clayton, F Cleva, E Coccia, C N Colacino, J Colas, A Colla, M Colombini, R Conte, D Cook, T R Corbitt, N Cornish, A Corsi, C A Costa, J-P Coulon, D M Coward, D C Coyne, J D E Creighton, T D Creighton, A M Cruise, R M Culter, A Cumming, L Cunningham, E Cuoco, K Dahl, S L Danilishin, R Dannenberg, S D'Antonio, K Danzmann, K Das, V Dattilo, B Daudert, M Davier, G Davies, A Davis, E J Daw, R Day, T Dayanga, R De Rosa, D DeBra, J Degallaix, M Del Prete, V Dergachev, R DeRosa, R DeSalvo, P Devanka, S Dhurandhar, L Di Fiore, A Di Lieto, I Di Palma, M Di Paolo Emilio, A Di Virgilio, M Diaz, A Dietz, F Donovan, K L Dooley, E E Doomes, S Dorsher, E S D Douglas, M Drago, R W P Drever, J C Driggers, J Dueck, J-C Dumas, T Eberle, M Edgar, M Edwards, A Effler, P Ehrens, R Engel, T Etzel, M Evans, T Evans, V Fafone, S Fairhurst, Y Fan, B F Farr, D Fazi, H Fehrmann, D Feldbaum, I Ferrante, F Fidecaro, L S Finn, I Fiori, R Flaminio, M Flanigan, K Flasch, S Foley, C Forrest, E Forsi, N Fotopoulos, J-D Fournier, J Franc, S Frasca, F Frasconi, M Frede, M Frei, Z Frei, A Freise, R Frey, T T Fricke, D Friedrich, P Fritschel, V V Frolov, P Fulda, M Fyffe, M Galimberti, L Gammaitoni, J A Garofoli, F Garufi, G Gemme, E Genin, A Gennai, I Gholami, S Ghosh, J A Giaime, S Giampanis, K D Giardina, A Giazotto, C Gill, E Goetz, L M Goggin, G González, M L Gorodetsky, S Gossler, R Gouaty, C Graef, M Granata, A Grant, S Gras, C Gray, R J S Greenhalgh, A M Gretarsson, C Greverie, R Grosso, H Grote, S Grunewald, G M Guidi, E K Gustafson, R Gustafson, B Hage, P Hall, J M Hallam, D Hammer, G Hammond, J Hanks, C Hanna, J Hanson, J Harms, G M Harry, I W Harry, E D Harstad, K Haughian, K Hayama, J-F Hayau, T Hayler, J Heefner, H Heitmann, P Hello, I S Heng, A W Heptonstall, M Hewitson, S Hild, E Hirose, D Hoak, K A Hodge, K Holt, D J Hosken, J Hough, E J Howell, D Hoyland, D Huet, B Hughey, S Husa, S H Huttner, T Huynh-Dinh, D R Ingram, R Inta, T Isogai, A Ivanov, P Jaranowski, W W Johnson, D I Jones, G Jones, R Jones, L Ju, P Kalmus, V Kalogera, S Kandhasamy, J B Kanner, E Katsavounidis, K Kawabe, S Kawamura, F Kawazoe, W Kells, D G Keppel, A Khalaidovski, F Y Khalili, E A Khazanov, H Kim, P J King, D L Kinzel, J S Kissel, S Klimenko, V Kondrashov, R Kopparapu, S Koranda, I Kowalska, D Kozak, T Krause, V Kringel, S Krishnamurthy, B Krishnan, A Królak, G Kuehn, J Kullman, R Kumar, P Kwee, M Landry, M Lang, B Lantz, N Lastzka, A Lazzarini, P Leaci, J Leong, I Leonor, N Leroy, N Letendre, J Li, T G F Li, N Liguori, H Lin, P E Lindquist, N A Lockerbie, D Lodhia, M Lorenzini, V Loriette, M Lormand, G Losurdo, P Lü, J Luan, M Lubinski, A Lucianetti, H Lück, A D Lundgren, B Machenschalk, M MacInnis, M Mageswaran, K Mailand, E Majorana, C Mak, I Maksimovic, N Man, I Mandel, V Mandic, M Mantovani, F Marchesoni, F Marion, S Márka, Z Márka, E Maros, J Marque, F Martelli, I W Martin, R M Martin, J N Marx, K Mason, A Masserot, F Matichard, L Matone, R A Matzner, N Mavalvala, R McCarthy, D E McClelland, S C McGuire, G McIntyre, G McIvor, D J A McKechan, G Meadors, M Mehmet, T Meier, A Melatos, A C Melissinos, G Mendell, D F Menéndez, R A Mercer, L Merill, S Meshkov, C Messenger, M S Meyer, H Miao, C Michel, L Milano, J Miller, Y Minenkov, Y Mino, S Mitra, V P Mitrofanov, G Mitselmakher, R Mittleman, B Moe, M Mohan, S D Mohanty, S R P Mohapatra, D Moraru, J Moreau, G Moreno, N Morgado, A Morgia, T Morioka, K Mors, S Mosca, V Moscatelli, K Mossavi, B Mours, C M Mow-Lowry, G Mueller, S Mukherjee, A Mullavey, H Müller-Ebhardt, J Munch, P G Murray, T Nash, R Nawrodt, J Nelson, I Neri, G Newton, A Nishizawa, F Nocera, D Nolting, E Ochsner, J O'Dell, G H Ogin, R G Oldenburg, B O'Reilly, R O'Shaughnessy, C Osthelder, D J Ottaway, R S Ottens, H Overmier, B J Owen, A Page, G Pagliaroli, L Palladino, C Palomba, Y Pan, C Pankow, F Paoletti, M A Papa, S Pardi, M Pareja, M Parisi, A Pasqualetti, R Passaquieti, D Passuello, P Patel, D Pathak, M Pedraza, L Pekowsky, S Penn, C Peralta, A Perreca, G Persichetti, M Pichot, M Pickenpack, F Piergiovanni, M Pietka, L Pinard, I M Pinto, M Pitkin, H J Pletsch, M V Plissi, R Poggiani, F Postiglione, M Prato, V Predoi, L R Price, M Prijatelj, M Principe, R Prix, G A Prodi, L Prokhorov, O Puncken, M Punturo, P Puppo, V Quetschke, F J Raab, D S Rabeling, T Radke, H Radkins, P Raffai, M Rakhmanov, B Rankins, P Rapagnani, V Raymond, V Re, C M Reed, T Reed, T Regimbau, S Reid, D H Reitze, F Ricci, R Riesen, K Riles, P Roberts, N A Robertson, F Robinet, C Robinson, E L Robinson, A Rocchi, S Roddy, C Röver, L Rolland, J Rollins, J D Romano, R Romano, J H Romie, D Rosińska, S Rowan, A Rüdiger, P Ruggi, K Ryan, S Sakata, M Sakosky, F Salemi, L Sammut, L Sancho de la Jordana, V Sandberg, V Sannibale, L Santamaría, G Santostasi, S Saraf, B Sassolas, B S Sathyaprakash, S Sato, M Satterthwaite, P R Saulson, R Savage, R Schilling, R Schnabel, R M S Schofield, B Schulz, B F Schutz, P Schwinberg, J Scott, S M Scott, A C Searle, F Seifert, D Sellers, A S Sengupta, D Sentenac, A Sergeev, D A Shaddock, B Shapiro, P Shawhan, D H Shoemaker, A Sibley, X Siemens, D Sigg, A Singer, A M Sintes, G Skelton, B J J Slagmolen, J Slutsky, J R Smith, M R Smith, N D Smith, K Somiya, B Sorazu, F C Speirits, L Sperandio, A J Stein, L C Stein, S Steinlechner, S Steplewski, A Stochino, R Stone, K A Strain, S Strigin, A S Stroeer, R Sturani, A L Stuver, T Z Summerscales, M Sung, S Susmithan, P J Sutton, B Swinkels, G P Szokoly, D Talukder, D B Tanner, S P Tarabrin, J R Taylor, R Taylor, P Thomas, K A Thorne, K S Thorne, E Thrane, A Thüring, C Titsler, K V Tokmakov, A Toncelli, M Tonelli, O Torre, C Torres, C I Torrie, E Tournefier, F Travasso, G Traylor, M Trias, J Trummer, K Tseng, L Turner, D Ugolini, K Urbanek, H Vahlbruch, B Vaishnav, G Vajente, M Vallisneri, J F J van den Brand, C Van Den Broeck, S van der Putten, M V van der Sluys, A A van Veggel, S Vass, R Vaulin, M Vavoulidis, A Vecchio, G Vedovato, J Veitch, P J Veitch, C Veltkamp, D Verkindt, F Vetrano, A Viceré, A E Villar, J-Y Vinet, H Vocca, C Vorvick, S P Vyachanin, S J Waldman, L Wallace, A Wanner, R L Ward, M Was, P Wei, M Weinert, A J Weinstein, R Weiss, L Wen, S Wen, P Wessels, M West, T Westphal, K Wette, J T Whelan, S E Whitcomb, D White, B F Whiting, C Wilkinson, P A Willems, L Williams, B Willke, L Winkelmann, W Winkler, C C Wipf, A G Wiseman, G Woan, R Wooley, J Worden, I Yakushin, H Yamamoto, K Yamamoto, D Yeaton-Massey, S Yoshida, P Yu, M Yvert, M Zanolin, L Zhang, Z Zhang, C Zhao, N Zotov, M E Zucker, J Zweizig, .
Phys. Rev. Lett.
PUBLISHED: 10-09-2011
Show Abstract
Hide Abstract
The gravitational-wave (GW) sky may include nearby pointlike sources as well as stochastic backgrounds. We perform two directional searches for persistent GWs using data from the LIGO S5 science run: one optimized for pointlike sources and one for arbitrary extended sources. Finding no evidence to support the detection of GWs, we present 90% confidence level (C.L.) upper-limit maps of GW strain power with typical values between 2-20×10(-50)??strain(2)?Hz(-1) and 5-35×10(-49)??strain(2)?Hz(-1)?sr(-1) for pointlike and extended sources, respectively. The latter result is the first of its kind. We also set 90% C.L. limits on the narrow-band root-mean-square GW strain from interesting targets including Sco X-1, SN 1987A and the Galactic center as low as ?7×10(-25) in the most sensitive frequency range near 160 Hz.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.